A randomized, double-blind, placebo-controlled multi-centre phase II study to evaluate efficacy and tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Trial Profile

A randomized, double-blind, placebo-controlled multi-centre phase II study to evaluate efficacy and tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Alendronic acid/guanidine dextran conjugate (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors DexTech Medical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2016 Status changed from recruiting to discontinued.
    • 03 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top